Does Selank need a reducing agent in buffer?

No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.

Is Selank less light-sensitive than other peptides?

It lacks the methionine whose photo-accelerated oxidation drives that concern elsewhere. Dark storage remains sensible practice but the specific liability is absent.

Why avoid shaking the vial?

Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence. Swirl instead.

Selank Storage, Stability and Reconstitution

The short answer

Selank lacks methionine, cysteine, asparagine and glutamine, between them the source of methionine oxidation, disulfide scrambling and deamidation, which account for most peptide degradation in practice. What remains is hydrolysis, plus one practical difficulty: no aromatic residue means no 280 nm quantification.

Key facts

Supplied as: White lyophilised powder
Disulfide risk: None (no cysteine)
Oxidation risk: Low (no methionine)
Deamidation risk: None (no Asn or Gln)
Main route: Hydrolysis, resisted by three prolines
Lyophilised storage: Cold, dry, dark
Freeze-thaw: Avoid by aliquoting

The residue Selank does not have

Semax, built by the same institute using the same design method, carries a methionine at position 1, and that single residue is the whole story of its handling, because the thioether sulfur oxidises to the sulfoxide and adds 16 Da. Selank has no methionine anywhere in TKPRPGP. The degradation route that dominates guidance for Semax, and for MOTS-c with its two methionines, simply does not exist here.

Nor does it have the other two

No cysteine, so no disulfide bonds to form or scramble and no reducing agent needed in buffer. No asparagine and no glutamine, so deamidation is off the table as well. Between them, methionine oxidation, disulfide scrambling and deamidation account for most of what goes wrong with research peptides in practice. Selank is vulnerable to none of them.

Research material referenced

Selank 10mg, third-party HPLC tested

Buy Selank · £24.99

What is left to go wrong

Hydrolysis of the peptide backbone, and physical loss to container surfaces. A real concern for small quantities of a highly charged peptide, which adsorbs to glass and plastic more readily than a neutral one. Three prolines in seven residues resist enzymatic cleavage well, but proline confers no protection against simple chemical hydrolysis in solution over time. The general case for keeping lyophilised peptide cold, dry and dark is set out under bacteriostatic water; it applies here, just for a narrower set of reasons than usual.

The quantification problem

This is where Selank is harder to work with than Semax rather than easier. TKPRPGP contains no tryptophan, no tyrosine and no phenylalanine, so it has no absorbance near 280 nm. The wavelength every standard spectrophotometric peptide assay relies on. Semax has phenylalanine and histidine; DSIP has a tryptophan. Selank has nothing, and concentration has to be established by another route entirely.

Reconstitution

Introduce diluent gently down the vial wall rather than onto the powder, and swirl rather than shake. Foaming means an air-liquid interface has been created, and that is where peptides unfold and then aggregate. Selank is small, highly charged and very hydrophilic, so it goes into solution readily; difficulty dissolving at a concentration that previously worked is therefore a more informative warning sign here than it would be for a stubborn hydrophobic peptide.

After reconstitution

Aliquot into single-use volumes. Repeated freeze-thaw cycling concentrates solutes at the advancing ice boundary and creates fresh interfaces on every cycle, and neither is addressed by the absence of oxidation-prone residues. Selank's chemical robustness protects it from specific reactions, not from physical handling damage.

Frequently asked questions

Does Selank need a reducing agent in buffer?: No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.
Is Selank less light-sensitive than other peptides?: It lacks the methionine whose photo-accelerated oxidation drives that concern elsewhere. Dark storage remains sensible practice but the specific liability is absent.
Why avoid shaking the vial?: Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence. Swirl instead.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue, and that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin. That is an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed, as the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance: there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real (expression-level rather than direct allosteric modulation), but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum